Bezeq launches fiber-optic service
A 1 Gbps connection will cost NIS 119 monthly, which does not include payment to an ISP.
Bezeq Israeli Telecommunication Co. Ltd. (TASE: BEZQ) is launching its fiber-optic project and is due to hold a press conference today at which it will officially announce prices for the service and details of the rollout. The company has notified the Internet service providers (ISPs) in accordance with its obligations under the wholesale market rules, and the details were leaked at the weekend.
Bezeq will offer two packages, at speeds of 600 Mbps and 1 Gbps. The first package will cost subscribers NIS 109 monthly (excluding ISP cost), and the larger package will cost NIS 119 monthly. The ISPs charges will determine the overall cost to the consumer. These will probably be around NIS 20 monthly. Bezeq is obliged to sell Internet split between infrastructure and ISP, until the Ministry of Communications completes the abolition of its divided market policy.
Bezeq Announces New Fiber Optic Service for Superfast Internet | The Jewish Press - JewishPress com | Hana Levi Julian | 2 Nisan 5781 – March 14, 2021
jewishpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jewishpress.com Daily Mail and Mail on Sunday newspapers.
Study reveals potential risk factors for developing nerve damage after cancer treatment
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Premium Content
Subscriber only
A common medical treatment undertaken by hundreds of Central Queenslanders annually can potentially have dire health consequences, new research has revealed.
Led by University of NSW academics, the research team studied 333 adult patients between 2015 and 2020 receiving paclitaxel and oxaliplatin chemotherapy in hospitals and cancer clinics in Sydney and Brisbane.
Chemotherapy is the use of powerful chemical drugs to kill fast growing cancer cells in the body.
The research aimed to discover pre-treatment clinical and blood based risk factors in patients who developed chemotherapy-induced peripheral neuropathy.
Clinical and blood risk factors included age, weight and low red blood cell count.